ADSCs‐exo mitigates urethral stricture fibrosis by primarily suppressing the TGF‐β/Smad pathway, thereby downregulating the downstream PDGFR‐β/RAS/ERK axis, highlighting its therapeutic potential as a cell‐free therapeutic approach for fibrotic urethral disease. This evidence concerns the gene TGFB1 and urinary system disorder.